WO2014195850A3 - Compositions and methods for the treatment of neurologic diseases and neurological disorders - Google Patents
Compositions and methods for the treatment of neurologic diseases and neurological disorders Download PDFInfo
- Publication number
- WO2014195850A3 WO2014195850A3 PCT/IB2014/061893 IB2014061893W WO2014195850A3 WO 2014195850 A3 WO2014195850 A3 WO 2014195850A3 IB 2014061893 W IB2014061893 W IB 2014061893W WO 2014195850 A3 WO2014195850 A3 WO 2014195850A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- treatment
- compositions
- methods
- neurological disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for the treatment of neurologic diseases and neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain, diabetic neuropathy, seizures, creutzfeld-jacob disease, multiple sclerosis, back pain, parkinson's, obesity, bipolar depression, partial-onset seizures.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2465CH2013 | 2013-06-05 | ||
IN2465/CHE/2013 | 2013-06-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014195850A2 WO2014195850A2 (en) | 2014-12-11 |
WO2014195850A3 true WO2014195850A3 (en) | 2015-05-21 |
Family
ID=52008664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/061893 WO2014195850A2 (en) | 2013-06-05 | 2014-06-02 | Compositions and methods for the treatment of neurologic diseases and neurological disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014195850A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9505776B2 (en) | 2013-03-14 | 2016-11-29 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
NZ723269A (en) | 2014-02-24 | 2017-04-28 | Alkermes Pharma Ireland Ltd | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006037133A1 (en) * | 2004-09-29 | 2006-04-06 | Ceptor Corporation | Treatment of traumatic or degenerative neurologic, otologic, or ophthalmologic diseases with targeted protease inhibitors |
US8017581B1 (en) * | 2004-05-11 | 2011-09-13 | Centre National De La Recherche Scientifique (Cnrs) | MSH-agonist tripeptide conjugates |
WO2012149352A1 (en) * | 2011-04-29 | 2012-11-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid guanidine and salicylate guanidine derivatives and their uses |
WO2013027150A1 (en) * | 2011-08-21 | 2013-02-28 | Mahesh Kandula | Compositions and methods for the treatment of parkinson's disease |
-
2014
- 2014-06-02 WO PCT/IB2014/061893 patent/WO2014195850A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017581B1 (en) * | 2004-05-11 | 2011-09-13 | Centre National De La Recherche Scientifique (Cnrs) | MSH-agonist tripeptide conjugates |
WO2006037133A1 (en) * | 2004-09-29 | 2006-04-06 | Ceptor Corporation | Treatment of traumatic or degenerative neurologic, otologic, or ophthalmologic diseases with targeted protease inhibitors |
WO2012149352A1 (en) * | 2011-04-29 | 2012-11-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid guanidine and salicylate guanidine derivatives and their uses |
WO2013027150A1 (en) * | 2011-08-21 | 2013-02-28 | Mahesh Kandula | Compositions and methods for the treatment of parkinson's disease |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9505776B2 (en) | 2013-03-14 | 2016-11-29 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
Also Published As
Publication number | Publication date |
---|---|
WO2014195850A2 (en) | 2014-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013175377A3 (en) | Compositions and methods for treatment of mucositis | |
WO2014174425A3 (en) | Compositions and methods for the treatment of orthostasis and neurological diseases | |
MX2019007713A (en) | Compositions and methods for the treatment of chronic pain. | |
WO2013168006A3 (en) | Compositions and methods for the treatment of local pain | |
MX2021010046A (en) | A new therapeutical composition containing apomorphine as active ingredient. | |
WO2013175376A3 (en) | Compositions and methods for the treatment of local pain | |
WO2014068463A3 (en) | Compositions and methods for the treatment of inflammation and metabolic disorders | |
SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
WO2016046680A3 (en) | Compositions and methods for the treatment of liver metabolic diseases | |
WO2014087307A3 (en) | Compositions and methods for the treatment of metabolic syndrome and diabetes | |
WO2014091384A3 (en) | Compositions and methods for the treatment of mucositis | |
WO2014195850A3 (en) | Compositions and methods for the treatment of neurologic diseases and neurological disorders | |
WO2013175359A3 (en) | Compositions and methods for the treatment of multiple sclerosis | |
WO2014087323A3 (en) | Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases | |
WO2014097137A3 (en) | Compositions and methods for the treatment of seizures and neurologic diseases | |
WO2013167998A3 (en) | Compositions and methods for the treatment of autonomic and other neurological disorders | |
MX2019006163A (en) | Compositions and methods for the treatment of oral infectious diseases. | |
WO2013167989A3 (en) | Compositions and methods for the treatment of neurological disorders | |
WO2014006529A3 (en) | Compositions and methods for the treatment of moderate to severe pain | |
WO2014106804A3 (en) | Compositions and methods for the treatment of metabolic syndrome and diabetes | |
WO2014068459A3 (en) | Compositions and methods for the treatment of pain and neurological diseases | |
WO2013167984A3 (en) | Compositions and methods for the treatment of muscle pain | |
WO2014122621A3 (en) | Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases | |
WO2014068461A3 (en) | Compositions and methods for the treatment of acute inflammation | |
WO2017208088A3 (en) | Compositions and methods for the treatment of parkinson's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14808431 Country of ref document: EP Kind code of ref document: A2 |